Company maintains 2026 guidance and targets over $250M in annualized revenue by Q4, signaling growth confidence.
Lifemd reaffirmed its 2026 financial guidance, projecting revenue between $220M and $230M and adjusted EBITDA of $12M to $17M. The company aims to surpass a $250M run-rate revenue by the fourth quarter, reflecting optimism in its growth trajectory.
The guidance aligns with prior expectations and follows a period of expansion in its core markets. Analysts had anticipated the reaffirmation, though the $250M run-rate target suggests accelerated momentum in the latter half of the year.
Shares showed muted reaction in after-hours trading, as the update largely met market consensus.